Log In Sign up
The largest database of trusted experimental protocols

Model 907xl

Manufactured by Omron
Visit Supplier

The Omron Model 907XL is a laboratory equipment device designed for measuring blood pressure. It features an automatic inflation system and digital display to provide accurate and reliable readings.

Automatically generated - may contain errors

Lab products found in correlation

Model 907, by Omron (1 mentions)

Close spelling variants of this product

Model HEM-907XL

3 protocols using model 907xl

1

Standardized BP Measurement Protocols

Cited 3 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
In the SPRINT16 (link) and ACCORD-BP20 (link) trials, BP was measured seated using a similar oscillometric device (Model 907XL in SPRINT22 (link) and Model 907 in ACCORD-BP,20 (link) Omron Healthcare). A mean of 3 subsequent BP measurements was recorded as baseline and follow-up BP. BPs were measured after 5 minutes of rest in both SPRINT and ACCORD-BP.23 (link) BP measurements were scheduled at baseline, monthly for the first 3 months, and every 3 months thereafter in SPRINT. In the intensive group in ACCORD-BP, BP measurements were scheduled at baseline, every month for the first 4 months, and every 2 months thereafter; in the standard treatment group, BP measurements were scheduled at baseline, month 1, month 4, and every 4 months thereafter. For the present analysis, the treated SBP, DBP, and pulse pressure (PP) for each patient were computed by taking the mean of their BP measurement from month 3 to the last reading.
Li J., Somers V.K., Gao X., Chen Z., Ju J., Lin Q., Mohamed E.A., Karim S., Xu H, & Zhang L. (2021). Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg. JAMA Network Open, 4(2), e2037554.
+ Open protocol
+ Expand
2

SPRINT Systolic BP Interventions and Follow-Up

Check if the same lab product or an alternative is used in the 5 most similar protocols
An automated measurement device (Model 907XL, Omron Healthcare) was used to record BP at clinic visits after the participant had been seated for 5 minutes of quiet rest. The recorded BP was based on an average of three BP readings taken 1 minute apart. Participants were seen monthly for the first 3 months and every 3 months thereafter. Additional monthly visits were scheduled as needed. Lifestyle modification was encouraged, and antihypertensive medications were adjusted on the basis of clinical judgment to target a systolic BP <120 mm Hg in the intensive group and 135-139 mm Hg in the standard group.
Participant recruitment began on November 8, 2010, and a decision to terminate the SPRINT systolic BP interventions was taken on August 20, 2015, because the hazard ratio (HR) for the primary composite end point exceeded the monitoring boundary in favor of intensive systolic BP lowering at two consecutive time points. This analysis includes follow-up during the trial phase, that is, up to August 20, 2015.
Bansal S., Boucher R., Shen J., Wei G., Chertow G.M., Whelton P.K., Cushman W.C., Cheung A.K, & Beddhu S. (2024). Role of Diuretics in Cardiovascular Events and Mortality in Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis. Clinical journal of the American Society of Nephrology : CJASN, 19(5).
+ Open protocol
+ Expand
3

Longitudinal Cardiovascular and Renal Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols
Clinical and laboratory data were obtained at baseline and every 3 months until study completion. BP was determined at each clinic visit using an automated BP measurement system (Model 907XL, Omron Healthcare). The mean of three BP readings obtained 1 minute apart after 5 minutes of quiet rest were used. Trained study staff saw participants for standardized study visits initially monthly for 3 months, and then every 3 months until study completion. A structured interview was used in both randomized groups every 3 months to obtain self-reported cardiovascular disease outcomes. Study personnel collected and reviewed medical records for adjudication of study outcomes. The four-variable modified diet in renal disease (MDRD) equation was used to calculate the estimated glomerular filtration rate (eGFR).16 (link) Safety assessments were performed per protocol.13 ,14 (link) The median follow-up period during the trial was 3.2 years, and for all extended follow-up phase, which included measurements after discontinuation of randomization, was 3.9 years.
Keating T.J., Peloquin J.G., Rodionov V.I., Momcilovic D, & Borisy G.G. (1997). Microtubule release from the centrosome. Proceedings of the National Academy of Sciences of the United States of America, 94(10), 5078-5083.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!